AC Immune Demonstrates Enhanced Performance of First-in-class Parkinson’s Diagnostic Agent - Seite 2

AC Immune’s PET tracers are derived from the Company’s innovative Morphomer discovery platform, which accelerates the design, development and synthesis of conformation-specific small molecules to power successful diagnostic and therapeutic approaches. The Morphomer platform has produced multiple small molecules with clinical proof-of-concept that bind selectively to pathological forms of human proteins such as alpha-synuclein and Tau.

Based on proof-of-concept data presented at this year’s AAT-AD/PD conference, AC Immune announced that it advanced its SupraAntigen-derived anti-alpha-synuclein therapeutic antibody candidate from discovery into preclinical development. The combined potential of AC Immune’s therapeutic and diagnostic programs is based on the Company’s capabilities in precision medicine and may improve the diagnosis and treatment of alpha-synuclein pathologies, which are of increasing interest in Alzheimer’s disease (AD) and NeuroOrphan indications.

Dr. Capotosti’s presentation was titled Developing a novel alpha-synuclein positron emission tomography (PET) tracer for the diagnosis of a-synucleinopathies. Key highlights from the presentation include:

• ACI-3847, a first-generation alpha-synuclein-PET tracer, showed good brain uptake and very low non-specific retention in a first-in-human study in idiopathic PD patients and healthy volunteers
• The data on ACI-3847 suggested to test the PET tracer in alpha-synuclein-pathologies with higher levels of alpha-synuclein accumulation
• AC Immune’s Morphomer platform also led to the discovery of ACI-12589 with excellent target occupancy and signal specificity ex vivo and an expected optimal signal-to-noise ratio in patients
• Data presented will show ACI-12589 as a potential first- and best-in-class imaging agent for the diagnosis of PD

About AC Immune SA
AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company utilizes two proprietary platforms, SupraAntigen and Morphomer, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with six currently in clinical trials. It has collaborations with major pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company and Janssen Pharmaceuticals.